ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

Krishna Gundabolu; Andrew Goldsweig; Vijaya R. Bhatt; Scott A. Koepsell; James L. Harper

doi:10.1111/hae.13871

ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

Krishna Gundabolu, Andrew Goldsweig, Vijaya R. Bhatt, Scott A. Koepsell, James L. Harper

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e5-e8
Journal	Haemophilia
Volume	26
Issue number	1
DOIs	https://doi.org/10.1111/hae.13871
State	Published - Jan 1 2020

ASJC Scopus subject areas

Hematology
Genetics(clinical)

Access to Document

10.1111/hae.13871

Cite this

@article{c04028a4ee294a039cfa9c27d4286bc3,

title = "ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII",

author = "Krishna Gundabolu and Andrew Goldsweig and Bhatt, {Vijaya R.} and Koepsell, {Scott A.} and Harper, {James L.}",

note = "Funding Information: The authors Andrew Goidsweig and Scott Koepsell stated that they had no interests which might be perceived as posing a conflict or bias. Krishna Gundabolu: Scientific Advisory Board: Pfizer, Novartis, Blueprint medicines, Jazz Pharmaceuticals, BioMarin pharmaceuticals. Stock Holder: Geron and Portola Pharmaceuticals. Board membership: Member of national comprehensive cancer network (NCCN) cancer‐venous thromboembolism panel. Vijaya R. Bhatt: VRB reports receiving consulting fees from Pfizer, CSL Behring, Agios, Incyte, Partner Therapeutics and Abbvie, and research funding from Incyte, Tolero Pharmaceuticals, Inc, and National Marrow Donor Program. James Harper: Conducted research for NovoNordisk as a site primary investigator.",

year = "2020",

month = jan,

day = "1",

doi = "10.1111/hae.13871",

language = "English (US)",

volume = "26",

pages = "e5--e8",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

AU - Gundabolu, Krishna

AU - Goldsweig, Andrew

AU - Bhatt, Vijaya R.

AU - Koepsell, Scott A.

AU - Harper, James L.

N1 - Funding Information: The authors Andrew Goidsweig and Scott Koepsell stated that they had no interests which might be perceived as posing a conflict or bias. Krishna Gundabolu: Scientific Advisory Board: Pfizer, Novartis, Blueprint medicines, Jazz Pharmaceuticals, BioMarin pharmaceuticals. Stock Holder: Geron and Portola Pharmaceuticals. Board membership: Member of national comprehensive cancer network (NCCN) cancer‐venous thromboembolism panel. Vijaya R. Bhatt: VRB reports receiving consulting fees from Pfizer, CSL Behring, Agios, Incyte, Partner Therapeutics and Abbvie, and research funding from Incyte, Tolero Pharmaceuticals, Inc, and National Marrow Donor Program. James Harper: Conducted research for NovoNordisk as a site primary investigator.

PY - 2020/1/1

Y1 - 2020/1/1

UR - http://www.scopus.com/inward/record.url?scp=85074813982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074813982&partnerID=8YFLogxK

U2 - 10.1111/hae.13871

DO - 10.1111/hae.13871

M3 - Letter

C2 - 31694063

AN - SCOPUS:85074813982

SN - 1351-8216

VL - 26

SP - e5-e8

JO - Haemophilia

JF - Haemophilia

IS - 1

ER -

ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this